However, immunotherapeutic agents targeting the reduction of neuroinflammatory extracellular Aβ and tau proteins have failed in several clinical and animal trials in recent years, accompanied by serious immune-related side effects, suggesting a deficiency in the recognition of the immune mechanisms of AD (Wilcock et al., 2004; Sperling et al., 2012; Sevigny et al., 2016). Here, MAPT is linked to Alzheimer disease.